Should I buy or sell Connect Biopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CNTB shares. View CNTB analyst ratings or view top-rated stocks .

What is Connect Biopharma's stock price target for 2024?

2 brokers have issued twelve-month price targets for Connect Biopharma's shares. Their CNTB share price targets range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 322.1% from the stock's current price. View analysts price targets for CNTB or view top-rated stocks among Wall Street analysts .

How have CNTB shares performed in 2024?

Connect Biopharma's stock was trading at $1.18 on January 1st, 2024. Since then, CNTB shares have increased by 30.5% and is now trading at $1.54. View the best growth stocks for 2024 here .

Are investors shorting Connect Biopharma?

Connect Biopharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 115,500 shares, an increase of 7.5% from the March 15th total of 107,400 shares. Based on an average daily volume of 158,600 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the shares of the stock are short sold. View Connect Biopharma's Short Interest .

When did Connect Biopharma IPO?

Connect Biopharma (CNTB) raised $150 million in an IPO on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

How do I buy shares of Connect Biopharma?

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CNTB

Connect Biopharma (CNTB) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free CNTB Stock Alerts

$1.54

+0.02 (+1.32%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.45
▼
$1.58
50-Day Range: $1.11
▼
$2.20
52-Week Range: $0.53
▼
$2.84

Volume: 32,224 shs
Average Volume: 149,120 shs
Market Capitalization: $84.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.50

Get Connect Biopharma alerts:

Connect Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 322.1% Upside
$6.50 Price Target
Short Interest: Healthy
0.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.67
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.19 to ($0.43) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.96 out of 5 stars

Medical Sector

367th out of 911 stocks

Pharmaceutical Preparations Industry

159th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Connect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Connect Biopharma has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.22% of the float of Connect Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Connect Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Connect Biopharma has recently increased by 7.54%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Connect Biopharma does not currently pay a dividend.
Dividend Growth
Connect Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CNTB.

3.7

News and Social Media Coverage

News Sentiment
Connect Biopharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Connect Biopharma this week, compared to 1 article on an average week.
Search Interest
6 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
2 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Connect Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Connect Biopharma are expected to decrease in the coming year, from $0.19 to ($0.43) per share.
Price to Book Value per Share Ratio
Connect Biopharma has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Connect Biopharma Stock (NASDAQ:CNTB)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

CNTB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CNTB Stock News Headlines

April 18, 2024 | americanbankingnews.com

Connect Biopharma (NASDAQ:CNTB) Price Target Raised to $8.00 at HC Wainwright

April 17, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 16, 2024 | globenewswire.com

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

April 13, 2024 | americanbankingnews.com

Analysts Offer Predictions for Connect Biopharma Holdings Limited's FY2025 Earnings (NASDAQ:CNTB)

April 11, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic Partnerships

April 7, 2024 | marketwatch.com

ADRs Advance; Connect Biopharma Climbs 19%

April 1, 2024 | marketwatch.com

ADRs End Higher; Connect Biopharma Climbs 26%

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 19, 2024 | tmcnet.com

Connect Biopharma to Participate in H.C. Wainwright 2n? Annual Autoimmune & Inflammatory Disease Virtual Conference

March 19, 2024 | globenewswire.com

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

March 5, 2024 | msn.com

HC Wainwright & Co. Initiates Coverage of Connect Biopharma Holdings Limited - Depositary Receipt () (CNTB) with Buy Recommendation

February 22, 2024 | benzinga.com

Connect Biopharma Hldgs Stock (NASDAQ:CNTB) Dividends: History, Yield and Dates

February 12, 2024 | finance.yahoo.com

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

January 29, 2024 | finance.yahoo.com

Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?

December 15, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Connect Biopharma Holdings (CNTB) and Inspire Medical Systems (INSP)

December 15, 2023 | seekingalpha.com

CNTB Connect Biopharma Holdings Limited

December 12, 2023 | morningstar.com

Connect Biopharma Holdings Ltd ADR CNTB

December 12, 2023 | marketwatch.com

Connect Biopharma Shares Jump on Positive Results for Asthma Treatment Trial

December 12, 2023 | msn.com

Connect Biopharma gains as asthma candidate succeeds in mid-stage trial

December 12, 2023 | finance.yahoo.com

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

December 11, 2023 | finance.yahoo.com

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

November 30, 2023 | finance.yahoo.com

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

November 28, 2023 | finance.yahoo.com

Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?

November 21, 2023 | msn.com

Why Is Skin Disease-Focused Connect Biopharma Stock Lower Today?

November 21, 2023 | msn.com

Connect Biopharma stock rises on positive data from dermatitis mAb

November 21, 2023 | finance.yahoo.com

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

See More Headlines

Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CNTB
CUSIP: N/A
CIK: 1835268
Web: www.connectbiopharm.com
Phone: 18587271045
Fax: N/A
Employees: 100
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.50
High Stock Price Target: $8.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +327.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.86 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 55,070,000
Free Float: 42,626,000
Market Cap: $83.71 million
Optionable: Optionable
Beta: -0.61

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Wubin Pan M.B.A. (Age 59)
Ph.D., Co-Founder, President & Chairman of the Board of Directors
Dr. Zheng Wei Ph.D. (Age 60)
Co-Founder, CEO & Director
Mr. Steven Chan (Age 52)
Chief Financial Officer
Mr. Jiang Bian J.D.
General Counsel & Chief Compliance Officer
Dr. Lei Sun Ph.D. (Age 60)
VP of Biologics & Head of CMC
Dr. Raul Collazo Ph.D.
VP & Global Head of Medical Affairs
Dr. Malinda V. Longphre Ph.D.
VP & Head of US Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

BML Capital Management LLC
Bought 2,061,438 shares on 1/30/2024
Ownership: 3.743%

View All Institutional Transactions

CNTB Stock Analysis - Frequently Asked Questions

Should I buy or sell Connect Biopharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CNTB shares.
View CNTB analyst ratings or view top-rated stocks.
What is Connect Biopharma's stock price target for 2024?: 2 brokers have issued twelve-month price targets for Connect Biopharma's shares. Their CNTB share price targets range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 322.1% from the stock's current price.
View analysts price targets for CNTB or view top-rated stocks among Wall Street analysts.
How have CNTB shares performed in 2024?: Connect Biopharma's stock was trading at $1.18 on January 1st, 2024. Since then, CNTB shares have increased by 30.5% and is now trading at $1.54.
View the best growth stocks for 2024 here.
Are investors shorting Connect Biopharma?: Connect Biopharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 115,500 shares, an increase of 7.5% from the March 15th total of 107,400 shares. Based on an average daily volume of 158,600 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the shares of the stock are short sold.
View Connect Biopharma's Short Interest.

When did Connect Biopharma IPO?: Connect Biopharma (CNTB) raised $150 million in an IPO on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.
How do I buy shares of Connect Biopharma?: Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial